Selinexor in Patients With Advanced Thymic Epithelial Tumor Progressing After Primary Chemotherapy

Key facts

Sponsor

Georgetown University

Principal Investigator

Chul Kim, MD

Georgetown University

Intervention

Open Label Selinexor(drug)

Enrollment

8 enrolled

Eligibility

18 years · All sexes

Timeline

2018 – 2022

Study locations (2)

• Georgetown Lombardi Comprehensive Cancer Center, Washington D.C., District of Columbia, United States
• John Theurer Cancer Center - Hackensack University Medical Center, Hackensack, New Jersey, United States

Collaborators

Hackensack Meridian Health · Karyopharm Therapeutics Inc

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Thymic epithelial neoplasm

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE2NCT06311955
  Clinical Study of Postoperative Carbon Ion Radiotherapy for Thymus Tumor With Residual Tumor
  Jian Chen
• RECRUITINGNANCT05558644
  Characterisation of the Immune Infiltrate and Molecular Features of Thymic Epithelial Tumors Tumors (TETs) (IMMUNO-TET)
  Institut Curie

See all trials for Thymic epithelial neoplasm →